Cancer Commun: The efficacy and safety of bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) in the first-line treatment of unresectable, metastatic or relapsed non-squamous non-small cell lung cancer patients in China: a multi-center, Randomized, double-blind phase III trial

Lung cancer is a common malignant tumor worldwide

Lung cancer is a common malignant tumor worldwide

The study is a multi-center, randomized, double-blind phase III clinical study conducted in 67 research centers in China

The study is a multi-center, randomized, double-blind phase III clinical study conducted in 67 research centers in China

649 patients were randomly assigned to 324 patients in the LY01008 treatment group and 325 patients in the Avastin group

Efficacy evaluation

As of May 15, 2020, the ORR of the LY01008 group was 56.

As of May 15, 2020, the ORR of the LY01008 group was 56.

subsistence analysis

The treatment-related adverse events (TEAEs) in the two groups were 99.

The treatment-related adverse events (TEAEs) in the two groups were 99.

In summary, in China's advanced or recurrent non-squamous non-small cell lung cancer (NSCLC), LY01008 has the same efficacy and safety as Avastin

In summary, in China's advanced or recurrent non-squamous non-small cell lung cancer (NSCLC), LY01008 has the same efficacy and safety as Avastin

Original source:

Shi Y, Lei K, Jia Y, et al.

Shi Y, Lei K, Jia Y, et al.
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Cancer Commun (Lond).
2021 Jun 29.
doi: 10.
1002/cac2.
12179.
PMID: 34184418.


Leave a message here